glp-1 shortage The promise and peril of agonists: What we do (and don't) know as of August 2024 The GLP-1 shortage is real.
Description
These are your defensible assets
An important feature of GLP-1 RA use in type 2 diabetes is weight loss, which reduces insulin resistance and typically reaches a plateau after around 6 months of treatment
Through HDAC6 inhibition, the pathway promotes the removal of damaged cellular components, reducing oxidative stress and enhancing cellular repair mechanisms in retinal cells (Cai et al., 2017)
On August 1, 2024, North Carolina Medicaid launched coverage for glucagon-like peptide 1 (GLP-1s) drugs for weight loss despite the State Health Plan (SHP) ending coverage on April 1, 2024
Chart: GLP-1 search interest, via Google Trends
There are a few others, but these are the most commonly talked about and prescribed today, so well focus on them
